Johnson & Johnson (NYSE:JNJ) Shares Purchased by Harbour Capital Advisors LLC

Harbour Capital Advisors LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,383 shares of the company’s stock after buying an additional 120 shares during the quarter. Harbour Capital Advisors LLC’s holdings in Johnson & Johnson were worth $860,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of JNJ. Navis Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at $240,000. Berry Wealth Group LP lifted its position in Johnson & Johnson by 3.7% during the first quarter. Berry Wealth Group LP now owns 18,594 shares of the company’s stock valued at $3,084,000 after purchasing an additional 665 shares during the period. C2C Wealth Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at $208,000. Retirement Guys Formula LLC grew its position in Johnson & Johnson by 28.7% during the 1st quarter. Retirement Guys Formula LLC now owns 7,619 shares of the company’s stock worth $1,263,000 after purchasing an additional 1,698 shares during the period. Finally, Climber Capital SA raised its stake in shares of Johnson & Johnson by 5.3% during the 1st quarter. Climber Capital SA now owns 2,206 shares of the company’s stock valued at $366,000 after buying an additional 111 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.1%

JNJ stock opened at $152.33 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The business’s 50-day moving average is $153.95 and its 200 day moving average is $153.67. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The stock has a market cap of $366.52 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 2.31 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on JNJ shares. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Wall Street Zen upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 21st. Finally, Raymond James Financial cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.